Jiménez-Flores I, Arredondo-Armenta JM, López-Salinas KG, Arango-Mathieu MD, García-Fierro LA, Hernández-Basulto R

Language: Spanish
References: 26
Page: 39-44
PDF size: 459.88 Kb.

ABSTRACT

Loxoscelism, the medical condition resulting from the bite of spiders of the genus Loxosceles spp, represents a diagnostic challenge due to the lack of specific tests in our country and the variability in clinical presentation, ranging from localized pain and necrosis to systemic complications. This article proposes 3 tools to establish the diagnosis: The Rader criteria, the NOT RECLUSE mnemonic and the clinical progression. Regarding treatment, although there is still no international consensus, it is important not to neglect general wound care, anti-tetanus prophylaxis and even more important the early use of antivenom (faboterapeutic).

REFERENCES

1. Zúñiga-Carrasco IR, Caro Lozano J. Aspectos clínicos y epidemiológicosde la mordedura de arañas en México. RevistaHospital Medicine and Clinical Management. el 1 de marzo de

2. 2019;11(4):191–203.

3. Goldfrank LR, Kirstein R, Flomenbaum NE, Lewin NA, WeismanRS, Howland MA, et al. Toxicologic emergencies. 9na ed. Mc-Graw-Hill; 2015.

4. Werner Apt Baruch, Marisol Denegri Cartes, Leonor Jofré Morales.Guía para el Manejo de Mordedura de Araña de los Rincones-Loxosceles laeta. Chile; 2016.

5. Droppelmann K, Majluf-Cáceres P, Sabatini-Ugarte N, Valle E,Herrera H, Acuña D. Caracterización clínica y epidemiológicade 200 pacientes con loxoscelismo cutáneo y cutáneo visceralLoxoscelism. Experience in 200 patients. Rev Med Chile.2021;149:682–8.

6. Dias-Lopes C, Felicori L, Rubrecht L, Cobo S, Molina L, NguyenC, et.al. Generation and molecular characterization of a monoclonalantibody reactive with conserved epitope in sphingomyelinasesD from Loxosceles spider venoms. Vaccine. el 11 de abril de2014;32(18):2086–92.

7. Rey G, Isbister K, Newcastle CM, St E, Fan HW. Spider bite. TheLancet. 2011;378:2039–86.

8. Ángel Cardona-Hernández M, Barragán-Dessavre M, Victoria Muñoz-de Peña K, Cecilia Rodríguez Quintanilla I. Cutaneous loxoscelism.Rev Cent Dermatol Pascua. 2019;28(3):122–6.

9. Consejo de salubridad general. Diagnóstico y tratamiento de mordedurapor arañas venenosas. CENETEC guía de referencia rapida.2005;

10. Cesaroni E, González S. Loxoscelismo cutáneo: a propósito de 6casos. Arch Argent Dermatol. 2016;66(3):71–7.

11. Juckett G. Arthropod Bites. Am Fam Physician. 2013;88(12):841–7.

12. Erickson TB, Cheema N. Arthropod Envenomation in North America.Emerg Med Clin North Am. el 1 de mayo de 2017;35(2):355–75.

13. Monranchel-García L, Pinega-Galindo, Casarrubias-RamirezM. Evolución clínica de pacientes con loxoscelismo sistémicoy dermonecrótico en un hospital de tercer nivel. Med Int Mex.2017;33(1):18–27.

14. Karen D. Schilli RKR. SCIENCE OF MEDICINE Micro-Series:The Bite of the Loxosceles Reclusa. Obtundation and MyocardialInfarction in a case of Systemic Loxoscelism. Mo Med.2014;111(2):143–7.

15. Fegley M, Duarte-Chavez R, Stone L, Nanda S. Classic brownrecluse spider bite. Int J Acad Med. 2016;2(2):256–9.

16. Sams HH, Dunnick CA, Smith ML, King LE. Necrotic arachnidism.J Am Acad Dermatol. 2001;44(4):561–76.

17. Rader RK, Stoecker W V., Malters JM, Marr MT, Dyer JA. Seasonalityof brown recluse populations is reflected by numbers ofbrown recluse envenomations. Toxicon. Julio de 2012;60(1):1–3.

18. Stoecker W V., Vetter RS, Dyer JA. Not recluse-a mnemonic deviceto avoid false diagnoses of brown recluse spider bites. JAMADermatol. el 1 de mayo de 2017;153(5):377–8.

19. Nguyen N, Pandey M. Loxoscelism: Cutaneous and HematologicManifestations. Adv Hematol. 2019;2019.

20. Pauli I, Puka J, Gubert IC, Minozzo JC. The efficacy of antivenomin loxoscelism treatment. Toxicon. agosto de 2006;48(2):123–37.

21. Del Carmen Sánchez-Villegas M, Rodríguez-Álvarez D, Ortega-Carrillo C, Alagón-Cano A, Zaldívar-Cervera J, Loría-CastellanosJ, et al. Loxoscelismo sistémico en una mujer embarazada.Reportes breves Rev Med Inst Mex Seguro Soc. 2014;52(1):98–103.

22. Karim-Silva S, Becker-Finco A, Jiacomini IG, Boursin F, Leroy A,Noiray M, et al. Loxoscelism: Advances and challenges in the designof antibody fragments with therapeutic potential. Toxins (Basel).el 1 de abril de 2020;12(4).

23. Karim-Silva S, de Moura J, Noiray M, Minozzo JC, Aubrey N, AlvarengaLM, et al. Generation of recombinant antibody fragmentswith toxin-neutralizing potential in loxoscelism. Immunol Lett. el 1de agosto de 2016;176:90–6.

24. Silanes. Guía de tratamiento en intoxicaciones por animales ponzoñosos.Antivenenos innovacion biotecnológica.

25. Tambourgi D V., Gonçalves-de-Andrade RM, van den Berg CW.Loxoscelism: From basic research to the propozsal of new therapies.Toxicon. el 15 de diciembre de 2010;56(7):1113–1119.

26. Arán-Sekul T, Rojas JM, Subiabre M, Cruz V, Cortés W, Osorio L,et al. Heterophilic antibodies in sera from individuals without loxoscelismcross-react with phospholipase D from the venom of Loxoscelesand Sicarius spiders. Journal of Venomous Animals andToxins Including Tropical Diseases. el 26 de julio de 2018;24(18).